PHARMACEUTICAL COMPOSITION FOR GROWTH HORMONE DEFICIENCY THERAPY COMPRISING FUSED hGH PROTEIN Russian patent published in 2021 - IPC C07K14/61 C07K19/00 A61K38/27 A61P5/06 

FIELD: biotechnology.

SUBSTANCE: present invention relates to the area of biotechnology, specifically to a therapeutic fused protein based on human growth hormone and compositions thereof and can be used in growth hormone deficiency therapy. The proposed hGH GX-H9 fused protein comprises human growth hormone and hybrid Fc. Fused hGH GX-H9 protein is administered to the patient once a week at a dosage of 0.4 to 1.6 mg/kg per kg of the body weight of the patient or once every two weeks at a dosage of 0.8 to 3.2 mg/kg per kg of the body weight of the patient.

EFFECT: invention ensures extended time of presence of growth hormone in vivo so that the IGF-1 SDS value is maintained within the normal range for a long period of time.

9 cl, 10 dwg, 5 tbl, 5 ex